Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RADIATE-VT VAR-2022-01

99 years and younger
All genders
The principal hypothesis of the Varian CRA randomized trial is that Varian CRA is safer and provides at least equivalent efficacy compared to repeat CA for patients with high-risk refractory VT who have experienced VT recurrence after CA and are candidates for additional CA.
Learn More

LGH 2024-8 BMS JCAR-017-EAP

99 years and younger
All genders
This is an expanded access protocol that will be conducted at sites qualified and approved to treat subjects with lisocabtagene maraleucel. Sometimes when lisocabtagene maraleucel is manufactured the drug does not pass all the testing results to be called lisocabtagene maraleucel. The expanded access protocol will be used to allow …
Learn More

UPCC 26124 A Phase 2 Study of Alisertib in Combination with Endocrine Therapy in Patients with HR+, HER2-Negative Recurrent or Metastatic Breast Cancer

99 years and younger
All genders
This is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended …
Learn More

UPCC 31824: A LOng-term Follow-up Master Protocol for Participants who Received Cell or Gene Therapies in Other AstraZeneca StUdieS (LOCUS)

99 years and younger
All genders
This study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment. We would like to rely on WCG as the IRB of record for this study.
Learn More

UPCC 06024 A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia (BMT-CTN 2207)

99 years and younger
All genders
This study is a prospective, multicenter Phase II study with participants receiving haploidentical transplantation or unrelated donor transplantation for previously untreated severe aplastic anemia (SAA).
Learn More

NRG-LU007: RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial

99 years and younger
All genders
This trial will be testing if adding radiation to the immunotherapy drug atezolizumab for patients with extensive stage small cell lung cancer (ES-SCLC) can improve progression-free survival (phase II) and overall survival (phase III) when compared to atezolizumab alone. We would like to rely on CIRB as the IRB of …
Learn More

LGH 2016-36: PALLAS

99 years and younger
All genders
This is a prospective, two arm, multicenter randomized open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR + / HER2- early breast cancer (EBC).
Learn More

LGH 2023-46: S2302 Pragmatica

99 years and younger
All genders
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent …
Learn More

GOG 3096: Dose Optimization and Phase 3 Study of R-DXd versus Investigators Choice of Chemotherapy in Platinum-resistant Ovarian Cancer

99 years and younger
All genders
Phase 2: To evaluate BICR-assessed objective response rate at each dose level of R-DXd. Phase 3:To evaluate BICR-assessed objective response rate with R-DXd treatment compared with investigator's choice of paclitaxel, PLD, gemcitabine, or topotecan. Objectives, outcome measures, and endpoints are located in Tables 3.1 and 3.2 of the protocol. Phase …
Learn More

MM1YA-S01: A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Pat

99 years and younger
All genders
This study is being done to compare different experimental drug regimens to the usual treatment (cytarabine and daunorubicin) for acute myeloid leukemia (AML) to find out which options have the best outcomes. We would like to rely on CIRB as the IRB or record.
Learn More
891 - 900 of 930